This inventor holds 1 USPTO granted patent. Top assignee: University of Pennsylvania. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: John Hogenesch: Innovator in Tumor Suppression Research
Introduction
John Hogenesch is a notable inventor based in Wallingford, PA (US). He has made significant contributions to the field of cancer research, particularly in the area of tumor suppression. His innovative work has led to the development of methods and compositions that utilize splicing regulatory proteins.
Latest Patents
Hogenesch holds a patent for "Methods and compositions using splicing regulatory proteins involved in tumor suppression." This patent focuses on the diagnosis and prognosis of mammalian carcinoma or cancer derived from primary epithelial cells and tissue fibrosis. The methods are designed using newly identified epithelial cell-type specific splicing factors, ESRP1 and ESRP2, which play crucial roles in tumor suppression. The diagnostic reagents developed for detecting these splicing factors in nucleotide or protein form are instrumental in these methods. Additionally, therapeutic compositions can provide epithelial cells with these factors to maintain FGFR2 and assist in suppressing metastasis. The patent also describes a high throughput splicing assay to identify compounds that alter splicing events. RNCP1 is identified as a splicing factor and a diagnostic for conditions characterized by inappropriate FGFR2-splicing.
Career Highlights
Hogenesch is affiliated with the University of Pennsylvania, where he continues to advance his research in cancer biology. His work has garnered attention for its potential impact on cancer diagnostics and therapeutics.
Collaborations
Hogenesch has collaborated with notable colleagues, including Russ P Carstens and Trey Kyle Sato. Their combined expertise enhances the research efforts in the field of tumor suppression.
Conclusion
John Hogenesch's innovative contributions to cancer research exemplify the importance of splicing regulatory proteins in tumor suppression. His patent and ongoing work at the University of Pennsylvania highlight his commitment to advancing medical science and improving cancer treatment options.